Neurotoxin-mediated ­­potent activation of the axon degeneration regulator SARM1

  1. Andrea Loreto  Is a corresponding author
  2. Carlo Angeletti
  3. Weixi Gu
  4. Andrew Osborne
  5. Bart Nieuwenhuis
  6. Jonathan Gilley
  7. Peter Arthur-Farraj
  8. Elisa Merlini
  9. Adolfo Amici
  10. Zhenyao Luo
  11. Lauren Hartley-Tassell
  12. Thomas Ve
  13. Laura M Desrochers
  14. Qi Wang
  15. Bostjan Kobe
  16. Giuseppe Orsomando  Is a corresponding author
  17. Michael P Coleman  Is a corresponding author
  1. University of Cambridge, United Kingdom
  2. Polytechnic University of Marche, Italy
  3. University of Queensland, Australia
  4. Griffith University, Australia
  5. AstraZeneca, United States
  6. The University of Queensland, Australia

Abstract

Axon loss underlies symptom onset and progression in many neurodegenerative disorders. Axon degeneration in injury and disease is promoted by activation of the nicotinamide adenine dinucleotide (NAD)-consuming enzyme SARM1. Here, we report a novel activator of SARM1, a metabolite of the pesticide and neurotoxin vacor. Removal of SARM1 completely rescues mouse neurons from vacor-induced neuron and axon death in vitro and in vivo. We present the crystal structure the Drosophila SARM1 regulatory domain complexed with this activator, the vacor metabolite VMN, which as the most potent activator yet know is likely to support drug development for human SARM1 and NMNAT2 disorders. This study indicates the mechanism of neurotoxicity and pesticide action by vacor, raises important questions about other pyridines in wider use today, provides important new tools for drug discovery, and demonstrates that removing SARM1 can robustly block programmed axon death induced by toxicity as well as genetic mutation.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 1-7 and figure supplements. VMN-bound dSARM1ARM crystal structure has been deposited in the Protein Data Bank (PDB: 7M6K).

The following data sets were generated

Article and author information

Author details

  1. Andrea Loreto

    Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
    For correspondence
    al850@cam.ac.uk
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6535-6436
  2. Carlo Angeletti

    Department of Clinical Sciences (DISCO), Polytechnic University of Marche, Ancona, Italy
    Competing interests
    No competing interests declared.
  3. Weixi Gu

    School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia
    Competing interests
    Weixi Gu, receives research funding from Disarm Therapeutics, a wholly-owned subsidiary of Eli Lilly and Co., Cambridge, MA, USA, but they had no role in the research presented here..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1185-3557
  4. Andrew Osborne

    Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    Andrew Osborne, is affiliated with Ikarovec Ltd. The author has no financial interests to declare..
  5. Bart Nieuwenhuis

    Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2065-2271
  6. Jonathan Gilley

    Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9510-7956
  7. Peter Arthur-Farraj

    Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1239-9392
  8. Elisa Merlini

    Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    No competing interests declared.
  9. Adolfo Amici

    Department of Clinical Sciences (DISCO), Polytechnic University of Marche, Ancona, Italy
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1081-7749
  10. Zhenyao Luo

    School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia
    Competing interests
    Zhenyao Luo, receives research funding from Disarm Therapeutics, a wholly- owned subsidiary of Eli Lilly and Co., Cambridge, MA, USA, but they had no role in the research presented here..
  11. Lauren Hartley-Tassell

    Institute for Glycomics, Griffith University, Southport, Australia
    Competing interests
    No competing interests declared.
  12. Thomas Ve

    Institute for Glycomics, Griffith University, Brisbane, Australia
    Competing interests
    Thomas Ve, Thomas Ve receives research funding from Disarm Therapeutics, a wholly-owned subsidiary of Eli Lilly & Co., Cambridge, MA, USA, but they had no role in the research presented here..
  13. Laura M Desrochers

    Neuroscience, BioPharmaceuticals R and D, AstraZeneca, Waltham, United States
    Competing interests
    Laura M Desrochers, This work is in part funded by a BBSRC/AstraZeneca Industrial Partnership Award and Laura M Desrochers was an employee of AstraZeneca for part of the project. Laura M Desrochers is affiliated with Vertex Pharmaceuticals. The author has no financial interests to declare..
  14. Qi Wang

    Neuroscience, BioPharmaceuticals R and D, AstraZeneca, Waltham, United States
    Competing interests
    Qi Wang, This work is in part funded by a BBSRC/AstraZeneca Industrial Partnership Award and Qi Wang was an employee of AstraZeneca for part of the project. Qi Wang is affiliated with Kymera Therapeutics. The author has no financial interests to declare..
  15. Bostjan Kobe

    School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia
    Competing interests
    Bostjan Kobe, receives research funding from Disarm Therapeutics, a wholly-owned subsidiary of Eli Lilly and Co., Cambridge, MA, USA, but they had no role in the research presented here..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9413-9166
  16. Giuseppe Orsomando

    Department of Clinical Sciences (DISCO), Polytechnic University of Marche, Ancona, Italy
    For correspondence
    g.orsomando@staff.univpm.it
    Competing interests
    No competing interests declared.
  17. Michael P Coleman

    Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
    For correspondence
    mc469@cam.ac.uk
    Competing interests
    Michael P Coleman, holds funding jointly provided by AstraZeneca for academic research and consults for Nura Bio, but they had no role in the research presented here..

Funding

Wellcome Trust (210904/Z/18/Z)

  • Andrea Loreto

Wellcome Trust (206634)

  • Peter Arthur-Farraj

Biotechnology and Biological Sciences Research Council (BB/S009582/1)

  • Andrea Loreto
  • Jonathan Gilley
  • Michael P Coleman

UNIVPM (RSA 2016-18 and 2017-19)

  • Giuseppe Orsomando

Australian National Health and Medical Research Council (NHMRC 1160570)

  • Bostjan Kobe

Sight Research UK (SAC 041)

  • Andrew Osborne
  • Bart Nieuwenhuis

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All studies conformed to the institution's ethical requirements in accordance with the 1986 Animals (Scientific Procedures) Act under Project Licences PPL P98A03BF9 and PP1824519, and in accordance with the Association for Research in Vision and Ophthalmology's Statement for the Use of Animals in Ophthalmic and Visual Research.

Copyright

© 2021, Loreto et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,171
    views
  • 732
    downloads
  • 34
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Andrea Loreto
  2. Carlo Angeletti
  3. Weixi Gu
  4. Andrew Osborne
  5. Bart Nieuwenhuis
  6. Jonathan Gilley
  7. Peter Arthur-Farraj
  8. Elisa Merlini
  9. Adolfo Amici
  10. Zhenyao Luo
  11. Lauren Hartley-Tassell
  12. Thomas Ve
  13. Laura M Desrochers
  14. Qi Wang
  15. Bostjan Kobe
  16. Giuseppe Orsomando
  17. Michael P Coleman
(2021)
Neurotoxin-mediated ­­potent activation of the axon degeneration regulator SARM1
eLife 10:e72823.
https://doi.org/10.7554/eLife.72823

Share this article

https://doi.org/10.7554/eLife.72823

Further reading

    1. Biochemistry and Chemical Biology
    Parnian Arafi, Sujan Devkota ... Michael S Wolfe
    Research Article

    Missense mutations in the amyloid precursor protein (APP) and presenilin-1 (PSEN1) cause early-onset familial Alzheimer’s disease (FAD) and alter proteolytic production of secreted 38-to-43-residue amyloid β-peptides (Aβ) by the PSEN1-containing γ-secretase complex, ostensibly supporting the amyloid hypothesis of pathogenesis. However, proteolysis of APP substrate by γ-secretase is processive, involving initial endoproteolysis to produce long Aβ peptides of 48 or 49 residues followed by carboxypeptidase trimming in mostly tripeptide increments. We recently reported evidence that FAD mutations in APP and PSEN1 cause deficiencies in early steps in processive proteolysis of APP substrate C99 and that this results from stalled γ-secretase enzyme-substrate and/or enzyme-intermediate complexes. These stalled complexes triggered synaptic degeneration in a Caenorhabditis elegans model of FAD independently of Aβ production. Here, we conducted full quantitative analysis of all proteolytic events on APP substrate by γ-secretase with six additional PSEN1 FAD mutations and found that all six are deficient in multiple processing steps. However, only one of these (F386S) was deficient in certain trimming steps but not in endoproteolysis. Fluorescence lifetime imaging microscopy in intact cells revealed that all six PSEN1 FAD mutations lead to stalled γ-secretase enzyme-substrate/intermediate complexes. The F386S mutation, however, does so only in Aβ-rich regions of the cells, not in C99-rich regions, consistent with the deficiencies of this mutant enzyme only in trimming of Aβ intermediates. These findings provide further evidence that FAD mutations lead to stalled and stabilized γ-secretase enzyme-substrate and/or enzyme-intermediate complexes and are consistent with the stalled process rather than the products of γ-secretase proteolysis as the pathogenic trigger.

    1. Biochemistry and Chemical Biology
    2. Chromosomes and Gene Expression
    Kira A Cozzolino, Lynn Sanford ... Dylan J Taatjes
    Research Article

    Hyperactive interferon (IFN) signaling is a hallmark of Down syndrome (DS), a condition caused by Trisomy 21 (T21); strategies that normalize IFN signaling could benefit this population. Mediator-associated kinases CDK8 and CDK19 drive inflammatory responses through incompletely understood mechanisms. Using sibling-matched cell lines with/without T21, we investigated Mediator kinase function in the context of hyperactive IFN in DS over a 75 min to 24 hr timeframe. Activation of IFN-response genes was suppressed in cells treated with the CDK8/CDK19 inhibitor cortistatin A (CA), via rapid suppression of IFN-responsive transcription factor (TF) activity. We also discovered that CDK8/CDK19 affect splicing, a novel means by which Mediator kinases control gene expression. To further probe Mediator kinase function, we completed cytokine screens and metabolomics experiments. Cytokines are master regulators of inflammatory responses; by screening 105 different cytokine proteins, we show that Mediator kinases help drive IFN-dependent cytokine responses at least in part through transcriptional regulation of cytokine genes and receptors. Metabolomics revealed that Mediator kinase inhibition altered core metabolic pathways in cell type-specific ways, and broad upregulation of anti-inflammatory lipid mediators occurred specifically in kinase-inhibited cells during hyperactive IFNγ signaling. A subset of these lipids (e.g. oleamide, desmosterol) serve as ligands for nuclear receptors PPAR and LXR, and activation of these receptors occurred specifically during hyperactive IFN signaling in CA-treated cells, revealing mechanistic links between Mediator kinases, lipid metabolism, and nuclear receptor function. Collectively, our results establish CDK8/CDK19 as context-specific metabolic regulators, and reveal that these kinases control gene expression not only via TFs, but also through metabolic changes and splicing. Moreover, we establish that Mediator kinase inhibition antagonizes IFN signaling through transcriptional, metabolic, and cytokine responses, with implications for DS and other chronic inflammatory conditions.